IRVINE, Calif., Feb. 16 /PRNewswire-FirstCall/ -- CalbaTech, Inc. , an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, said today that as its wholly owned subsidiary, LifeStem, Inc., begins the processes, procedures and protocols necessary to collect and store autologous stem cells at its Stem Cell MicroBank(TM), it is heartened by recent medical announcements that continue to show the enormous potential for healing through the use of adult stem cells.
“It was noted in the health media recently that, as few as five years ago, at an American Heart Association annual meeting, only five presentations spoke about the usefulness of stem cells to possibly repair diseased hearts,” said Dan Fulkerson, President of LifeStem. “At the most recent heart association meeting, fully 25 percent of all papers presented were on this topic.”
“The results showing that many heart-failure patients in clinical trials have benefited from adult stem cell treatments shows the promise of using stem cells in diseased hearts to create new, healthy tissue,” Mr. Fulkerson said. “But this is only one of many research areas that have recently received widespread media attention.”
LifeStem’s President said that research in Chicago is showing that stem cells are causing remission against life-threatening, treatment resistant lupus, a chronic autoimmune disease mainly affecting women, and researchers at Rice University in Houston are showing how cultured adult stem cells can be made to grow new, healthy bone. Also, Indiana University School of Medicine scientists are involved in a clinical trial using stem cell injections to assist people with severe peripheral artery disease who face possible amputation because of poor blood circulation.
“We believe we are in exactly the right field at the right time with the opening of our Stem Cell MicroBank(TM) and we anticipate announcing further developments, and additional clients, in future months,” Mr. Fulkerson said.
CalbaTech also today announced that the Company is now a part of Standard & Poor’s Market Access Listing. Standard & Poor’s is the world’s foremost provider of independent indices, investment research, risk evaluation, independent credit ratings, data and valuation. It has played a leading role for more than 140 years in providing investors with independent benchmarks needed to feel confident about investment decisions. The link is at: http://reports.standardandpoors.com/aidata/maccess/c/clbe_374004_one.htm .
About LifeStem
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of “Cellular Logistics.” The Company’s focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. LifeStem, in addition to being the first company to offer micro collection of stem cells, is also the first company to offer a collection service that collects and stores two different types of stem cells. The Company has filed patent applications for an endoscopic stem cell delivery device and its novel Stem Cell MicroBank(TM) service.
About CalbaTech
CalbaTech, Inc. is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick@eandecommunications.com
Note: Certain statements in this news release may contain “forward-looking” information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
CalbaTech, Inc.
CONTACT: Paul Knopick of E&E Communications, +1-949-707-5365,pknopick@eandecommunications.com, for CalbaTech, Inc.
